Your session is about to expire
← Back to Search
CAPOX + Bevacizumab + Trastuzumab for Stomach Cancer
Study Summary
This trial is testing a combination of chemotherapy drugs, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the recruitment of participants for this trial still ongoing?
"According to clinicaltrials.gov, this particular study is no longer actively recruiting participants; it was initially posted on February 1st 2011 and the most recent update occurred July 18th 2022. Despite its status, there are a number of other trials currently enlisting candidates - 1533 in total."
What medical applications is capecitabine most frequently employed for?
"Capecitabine has proven to be a useful therapy for refractory fallopian tube carcinoma, recurrent platinum-resistant epithelial ovarian cancer, and other malignant neoplasms."
Have there been any other investigations concerning capecitabine?
"Currently, there is a wealth of studies examining the efficacy and safety profile of capecitabine. Specifically, 300 are in Phase 3 with 1002 still active overall. While primarily conducted at centres within Seattle, Washington, 47238 locations worldwide have joined this research initiative."
How many participants are participating in the clinical experiment?
"This clinical trial has since closed, with the last data update occurring on July 18th 2022. For those interested in other medical opportunities, 531 trials for esophageal neoplasms malignant and 1002 trials for capecitabine are currently looking for participants."
What adverse effects may ensue from capecitabine treatment?
"Capecitabine's safety was rated as a 2 since this is Phase 2 testing, indicating prior research has validated its security but not yet established its efficacy."
Share this study with friends
Copy Link
Messenger